Zydus Cadila has received the final approval from the USFDA to market Lurasidone Hydrochloride Tablets USP (US RLD - Latuda Tablets), in the strengths of 20 mg, 40 mg, 60 mg, 80 mg and 120 mg. It will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.
The medication is used to treat certain mental/mood disorders such as schizophrenia, depression associated with bipolar disorder. It may also help to decrease hallucinations (hearing/seeing things that are not there).
The group now has 257 approvals and has so far filed over 350 ANDAs since the commencement ofthe filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.336.2 as compared to the previous close of Rs. 337.3. The total number of shares traded during the day was 26945 in over 381 trades.
The stock hit an intraday high of Rs. 341.7 and intraday low of 336.2. The net turnover during the day was Rs. 9131873.